A Phase 1 Study of KITE-753 or KITE-363 in Patients With Relapsed/Refractory B-Cell Lymphoma: Initial Safety and Preliminary Efficacy of KITE-753 and Updated Results of KITE-363

Presenting Author: Saurabh Dahiya

Inpatient Versus Outpatient Administration of CAR T-cell Therapy in relapsed/refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL): Real-World 30- and 60-Day Costs and Resource Utilization

Presenting Author: Samuel Hong

Estimating the survival impact of not receiving CAR T-cell (CAR T) therapy when eligible in patients with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) in the United States (US)

Presenting Author: Frederick Locke

Systematic Literature Review of Characteristics Associated with Safety and Healthcare Resource Utilization Outcomes in Various Settings of Care for Chimeric Antigen Receptor T-Cell Therapy

Presenting Author: Samuel Hong

Visualizing Geographic Variation and Systemic Inequities of Disease Burden and CAR T-Cell Therapy Access in Multiple Myeloma in the US

Presenting Author: Brandon Blue

Anito-Cel's D-Domain Binder Has a Fast Off-Rate and Contributes to Its Differentiated Pharmacology Profile in Multiple Myeloma

Presenting Author: Kevin Hart

Impact of treatment and sequencing with CAR T-cell therapies and bispecific antibodies on long-term survival in 4L+ RRMM in the US: a simulation model

Presenting Author: Jodi Lipof